mTOR
Inhibitors was confirmed to have considerable therapeutic potential in a series of clinical studies on neuroendocrine tumors, renal cancer, breast cancer , on behalf of the drug is rapamycin derivative everolimus and temsirolimus. In patients with breast cancer often can be detected PI3K / Akt / mTOR pathway abnormalities, and ultimately through activation of mTOR making abnormal growth of cells. Researchers believe everolimus combined with aromatase inhibitors is new options in treatment of advanced breast cancer. In the treatment of renal cell carcinoma, temsirolimus is first to be approved in the US for metastatic renal cell carcinoma line treatment.
PI3K / Akt / mTOR signaling pathway and a plurality of intracellular signaling pathways involved in tumor occurrence and development, and there are complex links between pathways. As one of the
MTOR Inhibitor, although everolimus showed activity of some anti-tumor in the majority of solid tumors, there are still a lot of questions. First, everolimus monotherapy or another signaling pathway inhibitor combination is not completely interrupt transmission signal in such a large cellular network, it may need more intervention inhibitors, and among the best path important interaction mechanism must be clarified in advance. Second, the current lack of efficacy of everolimus predictors. Furthermore, Everolimus can be used as an immunosuppressive agent in organ transplant patients, whether to bring more interference is not known in patients with the immune system disorder cancer. In short, mTOR inhibitors has good results in clinical studies of anti-tumor, bring more treatment options for a variety of solid tumors such as NET, breast, kidney bring. While screening more precise treatment patients is a requirement of individualized cancer therapy ,also the direction of future development of mTOR inhibitors.
Conbottpharm could give you:
1. Best quality in your requirement
2. Competitive price in China market
3. Mature Technical support
4. Professional logistic support
All we want is win-win business. Send yr. inquiries, you will get it!